Lactate Dehydrogenase
Lactate Dehydrogenase (LDH), which catalyzes the inter-conversion of pyruvate and lactate.
Mammalian lactate dehydrogenase (LDH) comprises three major families of conserved enzymes that catalyse the reversible interconversion of pyruvate and lactate, a key metabolic step in glycolysis and other metabolic pathways. At least five LDH tetrameric isozymes are reported in somatic mammalian tissues, comprising LDHA and LDHB subunits, whereas LDHC4 is found only in mature testis and spermatozoa, where it is required for male fertility. Lactate dehydrogenase catalyzes the interconversion of pyruvate and lactate with concomitant interconversion of NADH and NAD+. At high concentrations of lactate, the enzyme exhibits feedback inhibition, and the rate of conversion of pyruvate to lactate is decreased. Dihydroorotate dehydrogenase (DHODH) is a key enzyme that catalyzes the oxidation of dihydroorotate (DHO) to produce orotate, a key step in pyrimidine biosynthesis.
Targets for Lactate Dehydrogenase
Products for Lactate Dehydrogenase
- Cat.No. Product Name Information
-
GC19012
(R)-GNE-140
?A TRK kinase (TKI) inhibitor
- GC32993 (S)-GNE-140 (S)-GNE-140 is the less active enantiomer of GNE-140 which can inhibit Lactate dehydrogenase A (LDHA).
- GC35106 3-Dehydrotrametenolic acid 3-?Dehydrotrametenolic acid, isolated from the sclerotium of Poria cocos, is a lactate dehydrogenase (LDH) inhibitor. 3-?Dehydrotrametenolic acid promotes adipocyte differentiation in vitro and acts as an insulin sensitizer in vivo. 3-?Dehydrotrametenolic acid induces apoptosis and has anticancer activity.
- GC38463 ASLAN003 ASLAN003 (ASLAN003) is an orally active and potent Dihydroorotate Dehydrogenase (DHODH) inhibitor with an IC50 of 35 nM for human DHODH enzyme. ASLAN003 inhibits protein synthesis via activation of AP-1 transcription factors. ASLAN003 induces apoptosis and substantially prolongs survival in acute myeloid leukemia (AML) xenograft mice.
- GC32838 BAY-2402234 A DHODH inhibitor
- GC34011 FX-11 (LDHA Inhibitor FX11) FX-11 (LDHA Inhibitor FX11) is a potent, selective, reversible and competitive lactate dehydrogenase A (LDHA) specific inhibitor, with a Ki of 8 μM. FX-11 (LDHA Inhibitor FX11) can effectively activate PKM2 (pyruvate kinase M2). FX-11 (LDHA Inhibitor FX11) reduces ATP levels and induces oxidative stress, ROS production and cell death. FX-11 (LDHA Inhibitor FX11) shows antitumor activity in lymphoma and pancreatic cancer xenografts.
- GC38604 Glomeratose A Glomeratose A is a lactate dehydrogenase inhibitor, isolated from Polygala tenuifolia.
- GC32694 GNE-140 racemate GNE-140 racemate is a racemate mixture of (R)-GNE-140 and (S)-GNE-140. GNE-140 racemate is a potent lactate dehydrogenase A (LDHA) inhibitor.
-
GC13464
GSK 2837808A
GSK2837808A is a selective inhibitor of lactate dehydrogenase A (LDHA) with IC50 of 2.
- GC39279 hDHODH-IN-1 hDHODH-IN-1 is a human dihydroorotate dehydrogenase (hDHODH) inhibitor.
- GC39392 Isomalt Isomalt (Palatinitol), a well-tolerated, non-toxic polyol and a protein-stabilizing excipient, stabilizes lactate dehydrogenase (LDH) moderately during freeze-drying, and performs better during storage.
- GC32931 LDH-IN-1 LDH-IN-1 is a novel pyrazole-based inhibitor of human lactate dehydrogenase (LDH) with IC50s of 32 and 27 nM for LDHA and LDHB, respectively.
- GC63795 LDHA-IN-3 LDHA-IN-3, as a selenobenzene compound, is a potent, noncompetitive lactate dehydrogenase (LDHA) inhibitor (IC50=145.2 nM). LDHA-IN-3 can be used for the research of cancer.
- GC50151 NHI 2 LDHA inhibitor
- GC18183 Nifurtimox Nifurtimox is an antiprotozoal agent (IC50s = 9.91, 12.28, and 10.44 μM against Taluahuén, LQ, and Brener strains of T.
- GC14851 Vidofludimus DHODH inhibitor